dagblog - Comments for "Living with Type 1 Diabetes When You Can’t Afford Insulin"

So the supposed middle class

PeraclesPlease — Sun, 10 Mar 2019 10:44:31 +0000

In reply to 1,000% increase overnight:

So the supposed middle class benefits of the 2017 GOP Tax Bailout for Rich People Plan go to pay for big pharma sucker scams like this. Her parents being kinda "lucky" that they can deduct against enough income to save perhaps 25-30% of what they lose. Except they're probably losing on the state tax deduction & others as well.

1,000% increase overnight:

artappraiser — Sun, 10 Mar 2019 06:14:08 +0000

In reply to Living with Type 1 Diabetes When You Can’t Afford Insulin

1,000% increase overnight:

Just got a text from my mom about my dad's insulin prescriptions. The prescription company called to inform them that the 90-day supply of Levemir, one of two insulins he takes, went from $95 to $946. Un-fucking-believable.
— Emily C. Singer (@CahnEmily) March 8, 2019

My dad is also a small business owner of a company where he and my mom are the only employees, so he has to buy an insurance policy just for them. My parents pay an insane amount for their premiums, yet also have high deductibles. /3
— Emily C. Singer (@CahnEmily) March 9, 2019

The pharma execs claimed

artappraiser — Thu, 28 Feb 2019 01:33:31 +0000

In reply to Living with Type 1 Diabetes When You Can’t Afford Insulin

The pharma execs claimed (falsely) that we get treatments first-- only if there's a good business model. Meningitis B vaccine was available in many other countries before the U.S. My daughter lived with the risk of meningitis for a year as a result. https://t.co/aC0S1GnY0P
— Elisabeth Rosenthal (@RosenthalHealth) February 27, 2019

How High Drug Prices Inflate

artappraiser — Wed, 27 Feb 2019 06:36:46 +0000

In reply to Living with Type 1 Diabetes When You Can’t Afford Insulin

How High Drug Prices Inflate C.E.O.s’ Pay

Pharmaceutical companies say their profits fund research and innovation in new medicines, but they are spending billions to enrich shareholders and executives.

Guest op-ed by William Lazonick and Öner Tulum @ NYTimes.com, Feb. 26

Mr. Lazonick is an emeritus professor of economics at the University of Massachusetts, Lowell. Mr. Tulum is a postdoctoral fellow at SOAS, University of London.